Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: Comparison with liver and intestinal glucuronidation and impact of albumin

Drug Metabolism and Disposition

Volumn 40, Issue 4, 2012, Pages 825-835

  Gill, Katherine L ^a   Houston, J Brian ^a   Galetin, Aleksandra ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; DICLOFENAC; EZETIMIBE; GEMFIBROZIL; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; LEVALLORPHAN; MYCOPHENOLIC ACID; NALOXONE; PROPOFOL; TELMISARTAN; TOLBUTAMIDE; VERAPAMIL; WARFARIN;

ACCURACY; ACIDITY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INTESTINE MICROSOME METABOLISM; KIDNEY CLEARANCE; KIDNEY MICROSOME METABOLISM; LIVER MICROSOME METABOLISM; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL;

ADULT; AGED; FEMALE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; KIDNEY; LIVER; MALE; METABOLIC CLEARANCE RATE; MICROSOMES; MIDDLE AGED; ORGAN SPECIFICITY; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; PROTEIN BINDING; SERUM ALBUMIN, BOVINE; SUBSTRATE SPECIFICITY; YOUNG ADULT;

BOVINAE;

EID: 84858404510     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043984     Document Type: Article

References (47)

1. Al-Jahdari WS, Yamamoto K, Hiraoka H, Nakamura K, Goto F, and Horiuchi R (2006) Prediction of total propofol clearance based on enzyme activities in microsomes from human kidney and liver. Eur J Clin Pharmacol 62:527-533.
2. Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, et al. (2007) Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab 8:33-45. (Pubitemid 46043890)
3. Bellemare J, Rouleau M, Harvey M, Popa I, Pelletier G, Têtu B, and Guillemette C (2011) Immunohistochemical expression of conjugating UGT1A-derived isoforms in normal and tumoral drug-metabolizing tissues in humans. J Pathol 223:425-435.
4. Bernard O and Guillemette C (2004) The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos 32:775-778. (Pubitemid 38955603)
5. Boase S and Miners JO (2002) In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol 54:493-503. (Pubitemid 35356875)
6. Bowalgaha K and Miners JO (2001) The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
7. Cheng Z, Radominska-Pandya A, and Tephly TR (1999) Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 27:1165-1170. (Pubitemid 29463603)
8. Court MH (2010) Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 42:209-224.
9. Cubitt HE, Houston JB, and Galetin A (2009) Relative importance of intestinal and hepatic glucuronidation - impact on the prediction of drug clearance. Pharm Res 26:1073-1083.
10. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566. (Pubitemid 30238515)
11. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297. (Pubitemid 33136266)
12. Gaganis P, Miners JO, Brennan JS, Thomas A, and Knights KM (2007) Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. J Pharmacol Exp Ther 323:422-430. (Pubitemid 350005128)
13. Gertz M, Harrison A, Houston JB, and Galetin A (2010) Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 38:1147-1158.
14. Gertz M, Kilford PJ, Houston JB, and Galetin A (2008) Drug lipophilicity and microsomal protein concentration as determinants in the prediction of the fraction unbound in microsomal incubations. Drug Metab Dispos 36:535-542. (Pubitemid 351397979)
15. Hallifax D, Foster JA, and Houston JB (2010) Prediction of human metabolic clearance from in vitro systems: retrospective analysis and prospective view. Pharm Res 27:2150-2161.
16. Harbourt DE, Fallon JK, Ito S, Baba T, Ritter JK,Glish GL, and Smith PC (2012) Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal Chem 84:98-105.
17. Hoffmann K, Blaudszun J, Brunken C, Höpker WW, Tauber R, and Steinhart H (2005) New application of a subcellular fractionation method to kidney and testis for the determination of conjugated linoleic acid in selected cell organelles of healthy and cancerous human tissues. Anal Bioanal Chem 381:1138-1144. (Pubitemid 40512252)
18. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
19. Ishiguro N, Maeda K, Kishimoto W, Saito A, Harada A, Ebner T, Roth W, Igarashi T, and Sugiyama Y (2006) Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans. Drug Metab Dispos 34:1109-1115.
20. Ito K and Houston JB (2005) Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 22:103-112. (Pubitemid 40558152)
21. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, Aoki Y, Ikushiro S, Sakaki T, and Yokoi T (2009) Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 37:1759-1768.
22. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132. (Pubitemid 40386722)
23. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
24. Knights KM, Winner LK, Elliot DJ, Bowalgaha K, and Miners JO (2009) Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs. Br J Clin Pharmacol 68:402-412.
25. Lash LH, Putt DA, and Cai H (2008) Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. Toxicology 244:56-65. (Pubitemid 350299082)
26. Little JM, Kurkela M, Sonka J, Jäntti S, Ketola R, Bratton S, Finel M, and Radominska-Pandya A (2004) Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP- glucuronosyltransferases. J Lipid Res 45:1694-1703. (Pubitemid 39296209)
27. max values of UGT1A9. Drug Metab Dispos 39:2117-2129.
28. Mazoit JX, Sandouk P, Scherrmann JM, and Roche A (1990) Extrahepatic metabolism of morphine occurs in humans. Clin Pharmacol Ther 48:613-618.
29. Menochet K, Kenworthy KE, Houston JB, and Galetin A (2011) Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther doi:10.1124/jpet.111.187112.
30. Milne AM, Burchell B, and Coughtrie MW (2011) A novel method for the immunoquantification of UDP-glucuronosyltransferases in human tissue. Drug Metab Dispos 39:2258-2263.
31. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
32. Nishimura M and Naito S (2006) Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab Pharmacokinet 21:357-374.
33. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
34. Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwellinger E, Ebner T, et al. (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 40:83-92.
35. Raoof AA, van Obbergh LJ, de Ville de Goyet J, and Verbeeck RK (1996) Extrahepatic glucuronidation of propofol in man: possible contribution of gut wall and kidney. Eur J Clin Pharmacol 50:91-96. (Pubitemid 26140094)
36. Rowland A, Gaganis P, Elliot DJ,Mackenzie PI, Knights KM, andMiners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
37. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062. (Pubitemid 351717462)
38. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2009) Characterization of the binding of drugs to human intestinal fatty acid binding protein (IFABP): potential role of IFABP as an alternative to albumin for in vitro-in vivo extrapolation of drug kinetic parameters. Drug Metab Dispos 37:1395-1403.
39. Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, Sakamoto A, Ishiguro N, Matsumaru T, Terasaki T, et al. (2012) Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. Drug Metab Dispos 40:93-103.
40. Shipkova M, Strassburg CP, Braun F, Streit F, Gröne HJ, Armstrong VW, Tukey RH, Oellerich M, and Wieland E (2001) Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132:1027-1034. (Pubitemid 32238908)
41. Soars MG, Burchell B, and Riley RJ (2002) In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390. (Pubitemid 34250317)
42. Soars MG, Riley RJ, Findlay KA, Coffey MJ, and Burchell B (2001) Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos 29:121-126. (Pubitemid 32112924)
43. Soars MG, Ring BJ, and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31:762-767. (Pubitemid 36617665)
44. Soydan AS, Tavares IA, Weech PK, Tremblay NM, and Bennett A (1996) High molecular weight phospholipase A2 and fatty acids in human colon tumours and associated normal tissue. Eur J Cancer 32:1781-1787. (Pubitemid 26306893)
45. Takizawa D, Hiraoka H, Goto F, Yamamoto K, and Horiuchi R (2005) Human kidneys play an important role in the elimination of propofol. Anesthesiology 102:327-330. (Pubitemid 40189080)
46. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199. (Pubitemid 37518547)
47. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616. (Pubitemid 30340694)